Classic Hodgkin Lymphoma Clinical Trial
Official title:
A Randomized Phase II Study of Rituximab With ABVD Versus Standard ABVD for Patients With Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score > 2)
This phase II trial studies how well combination chemotherapy with or without rituximab works in treating participants with stage III-IV classic Hodgkin lymphoma. Monoclonal antibodies, such as rituximab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin, vinblastine, and dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving rituximab with combination chemotherapy may work better in treating participants with classic Hodgkin lymphoma.
PRIMARY OBJECTIVES:
I. To evaluate the event free survival (EFS) following therapy with rituximab plus adriamycin
(doxorubicin hydrochloride), bleomycin, vinblastine, and dacarbazine (ABVD) or standard ABVD
in patients with newly diagnosed classical Hodgkin lymphoma who have poor prognosis defined
as International prognostic score (IPS) of > 2.
SECONDARY OBJECTIVES:
I. To compare the effect of the two treatment arms on positron emission tomography (PET) scan
results after 2 cycles of therapy.
II. To compare the effect of the two treatment arms on the level of circulating malignant
Hodgkin stem cells.
OUTLINE: Participants are randomized to 1 of 2 arms.
ARM A: Participants receive rituximab intravenously (IV) over 7 hours on days 1, 8, 15, and
22 of course 1 and on days 1 and 8 of course 2. Participants also receive doxorubicin
hydrochloride, bleomycin, vinblastine, and dacarbazine IV over 1 hour on days 1 and 15.
Treatment with ABVD repeats every 4 weeks for up to 6 courses in the absence of disease
progression or unacceptable toxicity.
ARM B: Participants receive doxorubicin hydrochloride, bleomycin, vinblastine, and
dacarbazine as in Arm A.
After completion of study treatment, participants are followed up every 3 months for the
first year, every 4 months for the second year, every 6 months for years 3-5, and then
annually thereafter.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03233347 -
Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03712202 -
Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
|
Phase 2 | |
Recruiting |
NCT05833984 -
Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02758717 -
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT01771107 -
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02166463 -
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
|
Phase 3 | |
Active, not recruiting |
NCT04788043 -
Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT06465446 -
A Study of IMM01 in Combiniation With Tiselizumab Versus Physician's Choice Chemotherapy in PD-(L)1-refractory Classical Hodgkin Lymphoma
|
Phase 3 | |
Recruiting |
NCT05955105 -
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT06235047 -
Liposomal Doxorubicin-containing Front-line Treatment in Elderly Patients With HL (HL-MVD)
|
||
Recruiting |
NCT06164275 -
Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT05179603 -
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
|
Phase 2 | |
Active, not recruiting |
NCT03907488 -
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
|
Phase 3 | |
Not yet recruiting |
NCT05949931 -
Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma
|
Phase 2 | |
Not yet recruiting |
NCT06377540 -
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
|
Phase 2 | |
Active, not recruiting |
NCT03057795 -
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
|
Phase 2 |